Safety and Effectiveness of CARE1.02 Spectacle Lens in Myopia Control
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 796 people enrolled
- Started
- 25 Apr 2023
- Ended
- 12 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CARE1.02
- Single-vision spectacle lens
- Record updated
- 12 March 2026
Who can take part
- Age
- 12 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 12 to 17 years
- Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -0.50 to -8.00 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.50 D
- Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
- The intraocular pressure of 10 to 21mmHg
- Volunteer to participate in this clinical trial with signature of the informed consent form
Who cannot take part
- Participation of the drug clinical trial within three month and the device clinical trial within one month
- Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
- History of eye injury or intraocular surgery
- Ocular disease, such as uveitis and other inflammatory diseases,glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
- Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
- Clinically abnormal slit-lamp findings
- Abnormal fundus examination
- Only one eye meets the inclusion criteria
- Unable to have regular follow-up
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
China is a major country in myopia, with the highest number of teenagers suffering from myopia. Controlling the progression of myopia and the related complications caused by axial elongation have clinical significance and social value. Currently. There is a lack of researches on the impact of specially designed myopia control spectacle lens in adolescents aged 12 and above. Therefore, The researchers plan to conduct a randomized controlled trial among myopia adolescents aged 12-17 in middle and high schools in Guangzhou, to test and verify the safety and effectiveness of CARE1.02 on myopia control compared with single-vision spectacle lens.
The 2 groups in the trial
- Intervention groupTreatment being tested
CARE1.02
Treatment: CARE1.02
- Control groupExisting treatment, for comparison
Single-vision spectacle lens
Treatment: Single-vision spectacle lens
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Effectiveness of CARE1.02 Spectacle Lens Versus Single-vision Spectacle Lens in Myopia Control: a Randomised Controlled Trial
- Record updated
- 12 March 2026